F. Hoffmann-La Roche Ltd: FDA approves Roche's Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

With Lunsumio, people with heavily pre-treated follicular lymphoma may experience remission with a chemotherapy-free, fixed-duration treatment that can be accessed in an outpatient settingResults from

Related Keywords

Japan ,United States ,Switzerland ,America ,Mabthera Rituxan ,Gazyva Gazyvaro ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Venclexta Venclyxto ,Birgit Masjost ,Loren Kalm ,Nathalie Altermatt ,Genentech ,World Health Organization ,Roche Group ,Health Professional Version ,Roche Group Media Relations ,With Lunsumio ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Cancer Incidence ,Global Lunsumio ,Hoffmann ,Oche ,Pproves ,Lunsumio ,First ,Glass ,Bispecific ,Ntibody ,Treat ,People ,Relapsed ,Refractory ,Follicular ,Lymphoma ,